Exelixis Stock Upgraded to Strong-Buy as Analysts Adjust Ratings

Exelixis (NASDAQ:EXEL) received a notable upgrade from Wall Street Zen, which raised its stock rating from “buy” to “strong-buy” in a research note released on Saturday. This positive assessment reflects a growing confidence among analysts in the biotechnology company’s future performance.

Several other investment firms have recently revised their ratings and target prices for Exelixis. The Royal Bank of Canada lowered its target price from $46.00 to $43.00, maintaining a “sector perform” rating. In contrast, Morgan Stanley increased its target from $48.00 to $49.00 and assigned an “equal weight” rating. Citigroup, however, adjusted its stance by downgrading Exelixis from “market outperform” to “underperform.” Stifel Nicolaus raised its price objective to $44.00 while retaining a “hold” rating. UBS Group also set a target of $41.00.

Overall, analyst consensus indicates a mix of ratings for Exelixis, with ten analysts recommending a “buy,” eleven suggesting a “hold,” and two advising a “sell.” According to data from MarketBeat.com, Exelixis currently holds a consensus rating of “hold” with an average target price of $46.94.

Recent Earnings and Insider Activity

Exelixis recently released its quarterly earnings results on February 10, 2024. The biotechnology firm reported earnings per share of $0.94, exceeding the consensus estimate of $0.74 by $0.20. The company’s revenue for the quarter reached $598.66 million, slightly below the anticipated $609.17 million. Year-over-year, Exelixis experienced a 5.6% increase in quarterly revenue. Analysts forecast earnings per share of $2.04 for the current year.

In related news, insider trading activity has been notable. Executive Vice President Patrick J. Haley sold 67,814 shares on February 17 for approximately $2.95 million, reducing his holdings by 15.08%. Following this transaction, he owns 381,908 shares valued at about $16.62 million. Similarly, Director Jack L. Wyszomierski sold 99,574 shares on February 18 for around $4.38 million, leading to a 26.24% reduction in his position. Over the past ninety days, insiders have sold a total of 362,849 shares worth approximately $15.92 million. Currently, corporate insiders hold 2.85% of the company’s stock.

Institutional Investor Engagement

Institutional investors have also been active with their stakes in Exelixis. Richardson Financial Services Inc. increased its holdings by 95.1% in the third quarter, now owning 599 shares valued at $25,000. Anchor Investment Management LLC expanded its position by 500.0%, acquiring 600 shares for the same value. Other notable investors include Motiv8 Investments LLC, Root Financial Partners LLC, and Acumen Wealth Advisors LLC, each purchasing new stakes in Exelixis in recent months. Overall, institutional investors currently own 85.27% of the company’s stock.

Exelixis is a biotechnology company focused on discovering, developing, and commercializing small molecule therapies primarily for cancer treatment. The firm leverages advanced genetic models and high-throughput screening in its research, concentrating on kinase inhibitors that impact tumor growth and metastasis. Key products include CABOMETYX® and COMETRIQ®.

As analysts continue to adjust their ratings and investors respond to market conditions, Exelixis remains a company to watch in the biotechnology sector.